Clinical Trials · NCT06951854

Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder

Phase
Phase 2
Recruitment status
Recruiting
Sponsor
Neuroventi Inc.
Enrollment
105
Start date
Apr 2025
Locations
1 site, South Korea
Primary endpoint
Change from baseline in the composite scores of the major domains of the Korean Vineland Adaptive Behavior Scales-II (K-Vineland-II) at Week 8 after administration.
View Petrelintide compound reference